$PKI (PerkinElmer Inc.)

$PKI {{ '2016-03-18T20:51:34+0000' | timeago}} • SEC

$PKI's revenue from Environmental Health segment for 2015 rose by 4% from last year. This increase was primarily due to revenue from its acquisition of Perten Instruments Group in Dec. 2014, as well as increased demand in its laboratory services business, which was partially offset by unfavorable impacts from foreign currency.

$PKI {{ '2017-09-15T20:27:17+0000' | timeago}} • Announcement

$PKI announced the upcoming retirement of Andy Wilson, SVP & CFO. To provide appropriate time to identify a successor CFO and ensure a smooth integration, Mr. Wilson will retire in August 2018. The company has engaged an executive recruiting firm to assist in the search to fill the CFO position.

$PKI {{ '2017-07-24T21:21:06+0000' | timeago}} • Announcement

$PKI BoD declared a regular quarterly dividend of $0.07 per share of common stock on July 24, 2017. This dividend is payable on Nov. 10, 2017 to all shareholders of record at the close of business on Oct. 20, 2017.

$PKI {{ '2017-06-19T12:54:47+0000' | timeago}} • Announcement

$PKI agreed to buy Euroimmun Medical Laboratory Diagnostics AG for about $1.3Bil in cash. The transaction is expected to close in 4Q17. The acquisition is expected to be accretive to $PKI's 2018 non-GAAP EPS by about $0.28-0.30. Also, $PKI is reaffirming its 2017 revenue and EPS guidance.

$PKI {{ '2017-05-04T20:54:11+0000' | timeago}} • Announcement

For FY17, $PKI expects GAAP EPS from continuing operations to be in the range of $2.16-2.28. On a non-GAAP basis, $PKI expects EPS to be in the range of $2.80-2.90.

$PKI {{ '2017-05-04T20:53:46+0000' | timeago}} • Announcement

During 1Q17, revenue from $PKI's Discovery & Analytical Solutions segment rose 1% rise in revenue to $361.8MM. Revenue from Diagnostics segment rose 8% YoY to $152.4MM.

$PKI {{ '2017-05-04T20:45:39+0000' | timeago}} • Announcement

Diagnostic tool maker $PKI's 1Q17 net income fell to $38.6MM, or $0.33 per share, compared to $47.4MM, or $0.38 per share during 1Q16. Revenue rose 3% YoY to $514Bil. Excluding items, $PKI earned $0.55 per share.

$VREX {{ '2017-05-01T21:40:24+0000' | timeago}} • Announcement

$VREX has completed the previously announced acquisition of the Medical Imaging business of $PKI for $276MM in cash, subject to post-closing adjustments. This acquisition is expected to add approx $140MM in annual sales to Varex.

$PKI {{ '2017-05-01T21:25:20+0000' | timeago}} • Announcement

$PKI said it completed the $276MM sale of its medical imaging business to $VREX. The sale was announced on December 22, 2016.

$PKI {{ '2017-04-28T20:43:22+0000' | timeago}} • Announcement

The Board of Directors of $PKI declared a regular quarterly dividend of $0.07 per share of common stock, payable on August 10, 2017 to all shareholders of record on July 21, 2017.

$PKI {{ '2017-04-05T12:55:32+0000' | timeago}} • Announcement

$PKI said novel research results of phase 1 clinical trial examines safety of using cord blood stem cells for treating children with Autism Spectrum Disorder (ASD). ASD is the name for a group of developmental disorders. ASD includes social, communication, and behavioral challenges. These problems can be mild, severe, or somewhere in between.

$PKI {{ '2017-02-02T21:51:03+0000' | timeago}} • Announcement

$PKI expects 2017 GAAP EPS from continuing operations of $2.06-2.16 and adjusted EPS of $2.75-2.85. CEO Robert Friel said $PKI has undertaken substantial steps to strengthen the organization, accelerate operational capabilities and increase focus on innovation, that better position it to improve revenue growth and lift profitability.

$PKI {{ '2017-02-02T21:49:07+0000' | timeago}} • Announcement

$PKI announced the divestiture of its Medical Imaging business in 4Q16. With the announcement, the company has moved the operating results of that business into discontinued operations thereby impacting comparability to previously issued financial guidance.

$PKI {{ '2017-02-02T21:48:53+0000' | timeago}} • Announcement

$PKI reported a decline in 4Q16 earnings due to higher income tax provision. Net income slid to $64.85MM or $0.59 per share from $68.25MM or $0.61 per share last year. Revenue declined to $566.77MM from $569.9MM. Adjusted EPS increased to $0.83 from $0.81.

$PKI {{ '2017-01-30T11:45:30+0000' | timeago}} • Announcement

$PKI's BoD declared a regular quarterly dividend of $0.07 per share of common stock. The dividend is payable on May 10, 2017 to all shareholders of record on April 14, 2017.

$PKI {{ '2017-01-09T21:38:22+0000' | timeago}} • Announcement

$PKI has entered into a definitive agreement to acquire Tulip Diagnostics Private Ltd. Based in Goa, India, Tulip is one of the largest domestic providers of in-vitro diagnostic reagents, kits and instruments to diagnostic labs and government and private healthcare facilities. The transaction is currently anticipated to close in 1Q17.

$PKI {{ '2016-12-22T13:42:12+0000' | timeago}} • Announcement

$PKI plans to sell its Medical Imaging business, a supplier of flat panel X-ray detectors that serve as components for industrial, medical and dental X-ray imaging systems, to $VAR. The transaction is expected to close in 1H17. CEO Robert Friel said the divestiture will allow $PKI to focus investments and accelerate growth in higher priority areas.

$VAR {{ '2016-12-22T13:25:00+0000' | timeago}} • Announcement

$VAR said it agreed to acquire the Medical Imaging business of $PKI as an addition to its Imaging Components business, for $276MM, which is slated to become an independent public company, Varex Imaging Corporation. The separation is expected to be complete in Jan. 2017.

$PKI {{ '2016-11-07T23:45:15+0000' | timeago}} • Webcast

$PKI stated that share repurchase would be determined considering the acquisition opportunities and the availability of shares. $PKI would acquire companies that add value and the company is actively looking at acquisitions that could close in the coming quarters.

$PKI {{ '2016-11-07T23:24:56+0000' | timeago}} • Webcast

From 4Q16, $PKI will report segment results as Diagnostics and Discovery and Analytical Solutions (DAS). Until 3Q16, the company reported its division results as Human Health segment and Enviornmental Health segment.

$PKI {{ '2016-11-07T23:10:40+0000' | timeago}} • Webcast

$PKI believes that its new product introductions this year will generate an incremental $40MM in revenue. The company widened its 4Q16 revenue guidance to $610-620MM, representing low-single digit organic revenue growth and adjusted EPS of $0.85-0.87.

Recent Transcripts

PSDV (pSivida Corp.)
Monday, September 11 2017 - 8:30pm
AIRI (Air Industries Group)
Wednesday, August 16 2017 - 8:00pm
XRAY (DENTSPLY International Inc.)
Wednesday, August 9 2017 - 12:30pm
CVU (CPI Aerostructures Inc.)
Tuesday, August 8 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
PKI (PerkinElmer Inc.)
Thursday, August 3 2017 - 9:00pm
FLDM (Fluidigm Corporation)
Thursday, August 3 2017 - 9:00pm
INTT (inTEST Corp.)
Thursday, August 3 2017 - 9:00pm
PACB (Pacific Biosciences of California, Inc.)
Wednesday, August 2 2017 - 8:30pm
COHR (Coherent Inc.)
Tuesday, August 1 2017 - 8:30pm
ILMN (Illumina Inc.)
Tuesday, August 1 2017 - 8:30pm
LBY (Libbey Inc.)
Tuesday, August 1 2017 - 3:00pm
XYL (Xylem Inc.)
Tuesday, August 1 2017 - 1:00pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, August 1 2017 - 12:30pm
SNE (Sony Corporation)
Tuesday, August 1 2017 - 8:15am
ROP (Roper Technologies, Inc.)
Monday, July 31 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, July 27 2017 - 8:30pm
LH (Laboratory Corp. of America Holdings)
Wednesday, July 26 2017 - 1:00pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, July 26 2017 - 12:30pm

AlphaGraphics you may like